Kennedy Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Kennedy Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-176,809	Closed	-$743K	–	710
2023 Q1	$743K	Buy	176,809 +238	+0.1%	+$1.24K	0.02%	516
2022 Q4	$1.06M	Sell	176,571 -135	-0.1%	-$737	0.03%	488
2022 Q3	$1.03M	Sell	176,706 -323,728	-65%	-$2.02M	0.03%	476
2022 Q2	$2.99M	Sell	500,434 -132,825	-21%	-$680K	0.08%	369
2022 Q1	$2.96M	Sell	633,259 -95,136	-13%	-$284K	0.07%	393
2021 Q4	$1.81M	Buy	728,395 +224,013	+44%	+$548K	0.04%	463
2021 Q3	$1.49M	Buy	+504,382	New	+$1.37M	0.03%	492
2020 Q4	–	Sell	-10,000	Closed	-$22K	–	726
2020 Q3	$22K	Buy	+10,000	New	+$12.8K	﹤0.01%	646
2018 Q3	–	Sell	-394,505	Closed	-$1.97M	–	805
2018 Q2	$1.97M	Sell	394,505 -7,123	-2%	-$31.2K	0.04%	600
2018 Q1	$1.57M	Buy	401,628 +155,439	+63%	+$547K	0.03%	629
2017 Q4	$660K	Buy	+246,189	New	+$722K	0.01%	697

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Kennedy Capital Management's CTIC Position: Q2 2023 in Review

Kennedy Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 176,809 shares — an estimated $743K sold.

Kennedy Capital Management first reported a position in CTIC in Q4 2017 and held it in 11 quarters. The position peaked at $2.99M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Kennedy Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Kennedy Capital Management sold 176,809 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $743K.
Kennedy Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2017 and held it in 11 quarters.
Kennedy Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.99M in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Kennedy Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.